Myriad Genetics to Participate in Major Healthcare Investor Conferences in May-June 2025
Key Insights
Myriad Genetics (search), a leader in molecular diagnostic testing (search) and precision medicine (search), will participate in two major investor healthcare conferences in May and June 2025, providing opportunities to showcase their latest developments.
The company will hold a fireside chat at the BofA Securities (search) 2025 Health Care Conference on May 14 at 6:00 pm ET, followed by another presentation at the Goldman Sachs (search) 46th Annual Global Healthcare Conference on June 11.
These investor conferences come after Myriad's fourth quarter and full year 2024 financial results release on February 24, 2025, highlighting the company's continued engagement with the investment community.
Myriad Genetics (search), Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing (search) and precision medicine (search), has announced its participation in two upcoming major investor healthcare conferences in May and June 2025, continuing its active engagement with the investment community.
The company's management team will participate in a fireside chat at the BofA Securities (search) 2025 Health Care Conference on Wednesday, May 14, 2025, at 6:00 pm ET. Following this, they will present at the Goldman Sachs (search) 46th Annual Global Healthcare Conference, with a fireside chat scheduled for Wednesday, June 11, 2025, at 2:00 pm ET.
These appearances follow Myriad's earlier participation in several investor conferences in March 2025, including the TD Cowen 45th Annual Health Care Conference, the Raymond James 46th Annual Institutional Investors Conference, and the Leerink Global Healthcare Conference.
Recent Financial Performance
The upcoming investor conferences come after Myriad Genetics (search) released its fourth quarter and full year 2024 financial results on February 24, 2025. The company held an earnings conference call the same day to provide investors with a financial overview and business update on its performance.
Myriad Genetics (search) has maintained a consistent presence in the investment community, reflecting its position as a significant player in the genetic testing (search) and precision medicine (search) market. The company's continued engagement with investors suggests confidence in its business strategy and growth prospects.
Company Profile and Market Position
Myriad Genetics (search) has established itself as a leading provider of molecular diagnostic testing (search) and precision medicine (search) solutions. The company develops and offers genetic tests that help assess disease risk and guide treatment decisions across various medical specialties.
Their approach to precision medicine (search) aims to improve patient care while potentially lowering healthcare costs through more targeted treatment approaches. Myriad's diagnostic tests span multiple medical areas where genetic insights can significantly impact clinical decision-making.
Investor Access and Information
For those interested in following these presentations, Myriad Genetics (search) will provide live and archived webcasts of all presentations through their investor relations website at investor.myriad.com. This accessibility allows current and potential investors to stay informed about the company's latest developments and strategic direction.
The company maintains open communication channels with the investment community through its dedicated investor relations team, led by Matt Scalo, and its media relations department, headed by Kate Schraml.
Industry Context
Myriad's active participation in these high-profile healthcare investment conferences occurs against the backdrop of growing interest in precision medicine (search) and genetic testing (search). As healthcare continues to move toward more personalized approaches to diagnosis and treatment, companies with established positions in genetic and genomic testing are attracting significant attention from investors.
The precision medicine (search) market has seen substantial growth in recent years, driven by advances in genetic sequencing technologies, increased understanding of the genetic basis of diseases, and growing adoption of genetic testing (search) in clinical practice. Myriad's continued engagement with the investment community reflects the company's efforts to capitalize on these industry trends.